Clinical Application in Pediatric Myopia Management
The most significant clinical utility of Ortho-K is its proven ability to slow the progression of myopia in children and adolescents.
Research indicates that Ortho-K can reduce Axial Elongation—the physical lengthening of the eyeball—by 40% to 60% compared to traditional spectacles.
The mechanism behind this control is Peripheral Myopic Defocus. While the central flattening of the cornea provides clear central vision, the mid-peripheral steepening (the "red ring" seen on topography) causes light to focus in front of the peripheral retina. This optical signal is believed to trigger biochemical changes that inhibit the eye from growing too long.
Clinical studies highlight several key factors for success in pediatric cases:
Early Intervention: Children aged 6 to 9 years who are "rapid progressors" benefit most from early fitting to prevent the development of high myopia (over -6.00D).
Compliance: Success is highly dependent on consistent overnight wear (minimum 7–8 hours) and rigorous hygiene.
Combination Therapy: For children who continue to progress despite Ortho-K, the addition of low-dose Atropine (0.01%) has shown a synergistic effect, further slowing axial growth.
Children often report higher quality-of-life scores with Ortho-K, as it frees them from the need for glasses during sports, swimming, and daily school activities.